|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2007-3-26
|
|
pubmed:abstractText |
A persistently elevated or rising serum level of prostate-specific antigen (PSA) after radical prostatectomy is indicative of recurrent prostate cancer. The natural history of PSA-defined biochemical recurrence (BCR) is highly variable. While a rising PSA level universally antedates metastatic progression and prostate cancer-specific mortality (PCSM), it is not a surrogate for these endpoints. Thus, the management of patients with BCR is controversial.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0302-2838
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
51
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1175-84
|
|
pubmed:meshHeading |
pubmed-meshheading:17240528-Humans,
pubmed-meshheading:17240528-Male,
pubmed-meshheading:17240528-Neoplasm Metastasis,
pubmed-meshheading:17240528-Neoplasm Recurrence, Local,
pubmed-meshheading:17240528-Prognosis,
pubmed-meshheading:17240528-Prostate-Specific Antigen,
pubmed-meshheading:17240528-Prostatectomy,
pubmed-meshheading:17240528-Prostatic Neoplasms,
pubmed-meshheading:17240528-Recurrence,
pubmed-meshheading:17240528-Risk Assessment,
pubmed-meshheading:17240528-Salvage Therapy,
pubmed-meshheading:17240528-Tumor Markers, Biological
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy.
|
|
pubmed:affiliation |
Glickman Urological Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue A100, Cleveland, OH 44195, USA.
|
|
pubmed:publicationType |
Journal Article,
Review
|
